View Older Stories View More Recent Stories

Dec 18, 2017 07:33AM Intellia Therapeutics (NTLA) Names John Leonard, M.D., President and CEO
Dec 18, 2017 07:30AM Intellia Therapeutics Names John Leonard, M.D., President and Chief Executive Officer
Dec 11, 2017 07:00AM Intellia Therapeutics Announces New, Robust Genome Editing Data for Sickle Cell Disease at the American Society of Hematology Meeting
Nov 2, 2017 04:30PM Intellia Therapeutics to Present at November Healthcare Investor Conferences
Oct 31, 2017 07:30AM Intellia Therapeutics Announces Third Quarter 2017 Financial Results
Oct 30, 2017 04:35PM Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2017 Earnings
Oct 3, 2017 04:35PM Intellia Therapeutics to Present at October Healthcare Investor Conferences
Sep 26, 2017 07:30AM Intellia Therapeutics Demonstrates Sustained and Durable Genome Editing with CRISPR/Cas9 in One-Year Animal Study
Sep 7, 2017 05:00PM Intellia Therapeutics to Present at Upcoming September Investor Healthcare Conferences
Aug 1, 2017 07:30AM  Intellia Therapeutics Announces Second Quarter 2017 Financial Results
Jul 25, 2017 05:02PM CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), Caribou Biosciences and ERS Genomics Announce Appellate Brief Seeking Reversal of U.S. Patent Board Decision on CRISPR/Cas9 Gene Editing
Jul 25, 2017 05:00PM CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appellate Brief Seeking Reversal of U.S. Patent Board Decision on CRISPR/Cas9 Gene Editing
Jul 25, 2017 05:46AM Intellia Therapeutics (NTLA) Appoints Moncef Slaoui and Frank Verweil to Board
Jul 24, 2017 06:30PM Intellia Therapeutics Names Moncef Slaoui, Ph.D. and Frank Verwiel, M.D. to Its Board of Directors and Establishes a Science and Technology Committee
Jun 19, 2017 07:30AM Intellia Therapeutics (NTLA) Receives Patent for CRISPR/Cas Genome Editing in China
Jun 19, 2017 07:30AM Intellia Therapeutics Announces Patent for CRISPR/Cas Genome Editing in China
Jun 6, 2017 07:17AM Intellia Therapeutics (NTLA) & San Raffaele University Research Hospital Announce 3-Yr Collaboration to Combine CRISPR/Cas9 Genome Editing with Enhanced Cell Therapies to Fight Cancer
Jun 6, 2017 07:15AM Intellia Therapeutics and San Raffaele University and Research Hospital to Combine CRISPR/Cas9 Genome Editing with Enhanced Cell Therapies to Fight Cancer
May 15, 2017 05:47AM Intellia Therapeutics (NTLA) Reports Progress with CRISPR/Cas9 at the American Society of Gene & Cell Therapy Annual Meeting
May 13, 2017 08:40AM Intellia Therapeutics Announces Progress with CRISPR/Cas9 at the American Society of Gene & Cell Therapy Annual Meeting
May 2, 2017 07:30AM Intellia Therapeutics Announces First Quarter 2017 Financial Results
Apr 26, 2017 07:37AM Intellia (NTLA), CRISPR Therapeutics (CRSP) Receive U.S. Patent for CRISPR/Cas9 Ribonucleoprotein Complexes
Apr 26, 2017 07:30AM Intellia Therapeutics and CRISPR Therapeutics Announce U.S. Patent Covering CRISPR/Cas9 Ribonucleoprotein Complexes
Apr 13, 2017 07:36AM CRISPR (CRSP), Intellia (NTLA), Caribou, and ERS Genomics Appeal CRISPR/Cas9 U.S. Patent Board Decision
Apr 13, 2017 07:30AM CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appeal of CRISPR/Cas9 U.S. Patent Board Decision
Apr 11, 2017 07:31AM Intellia Therapeutics (NTLA) Granted CRISPR/Cas9 Genome Editing Technology Patent in Europe
Apr 11, 2017 07:30AM Intellia Therapeutics Announces European Patent Office’s Decision to Grant CRISPR/Cas9 Genome Editing Technology Patent
Mar 14, 2017 07:15AM Intellia Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results
Mar 8, 2017 07:36AM Intellia Therapeutics (NTLA) Reports Data Showing Increased Genome Editing Efficiency in Vivo and Durability Results with its CRISPR/Cas9 Technology
Mar 8, 2017 07:30AM Intellia Therapeutics Demonstrates Pioneering CRISPR/Cas9 Genome Editing Efficiency Data Using Lipid Nanoparticle Delivery Technology
Mar 1, 2017 07:10AM Intellia Therapeutics to Present at March Investor Healthcare Conferences
Feb 15, 2017 06:41PM Intellia Therapeutics to Hold Conference Call to Address Patent Interference Proceedings
Feb 15, 2017 03:19PM CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Provide Update on CRISPR/Cas9 U.S. Patent Interference Proceedings and Grants of Corresponding Patents in the U.K.
Feb 15, 2017 02:51PM CRISPR (CRSP), Intellia (NTLA), Caribou, ERS Genomics Provide Update on CRISPR/Cas9 U.S. Patent Interference Proceedings
Feb 15, 2017 02:49PM CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Provide Update on CRISPR/Cas9 U.S. Patent Interference Proceedings and Grants of Corresponding Patents in the U.K.
Feb 1, 2017 04:05PM Intellia Therapeutics to Present at Leerink Partners 6th Annual Global Healthcare Conference
Jan 11, 2017 04:39PM Intellia Therapeutics Joins Genomics England’s Industry Consortium
Dec 16, 2016 08:05AM CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), Caribou Biosciences, and ERS Genomics Enter Global License Agreement
Dec 16, 2016 08:00AM CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Global Agreement on the Foundational Intellectual Property for CRISPR/Cas9 Gene Editing Technology
Dec 13, 2016 09:21AM Intellia Therapeutics (NTLA) Appoints Graeme Bell as CFO
Dec 13, 2016 09:20AM Intellia Therapeutics Names Graeme Bell Chief Financial Officer
Dec 1, 2016 04:05PM Intellia Therapeutics Opens New Headquarters as Company Continues to Advance CRISPR/Cas9 Platform and Pipeline
Nov 1, 2016 04:05PM Intellia Therapeutics Reports Financial Results for Third Quarter 2016
Oct 31, 2016 07:00AM Intellia Therapeutics to Present at November Investor Healthcare Conferences
Oct 14, 2016 07:00AM Intellia Therapeutics to Present Data at the European Society of Gene & Cell Therapy Congress
Oct 5, 2016 07:00AM Intellia Therapeutics to Present at Jefferies Gene Editing/Therapy Summit
Sep 1, 2016 07:00AM Intellia Therapeutics to Present at September Investor Healthcare Conferences
Aug 18, 2016 09:37PM Intellia Therapeutics’ Preclinical Data Show Continued Progress in In Vivo Gene Editing With Systemic Lipid Nanoparticle Delivery of CRISPR/Cas9 components
Aug 10, 2016 04:05PM Intellia Therapeutics to Present at 2016 Wedbush PacGrow Healthcare Conference
Aug 4, 2016 04:10PM Intellia Therapeutics Reports Financial Results for Second Quarter 2016
View More Recent Stories View Older Stories